@article{cf4b82c5690241c99347b922bf8016a6,
title = "Radiologically isolated syndrome should be treated with disease-modifying therapy – Yes",
author = "Okuda, {Darin T.}",
note = "Funding Information: DTO received lecture fees from Acorda Therapeutics, Genentech, Genzyme, and Teva, advisory and consulting fees from EMD Serono, Genentech, Genzyme, Mallinckrodt, and Novartis, and research support from Biogen.",
year = "2017",
month = dec,
day = "1",
doi = "10.1177/1352458517729462",
language = "English (US)",
volume = "23",
pages = "1818--1819",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "14",
}